Immune Damage and Vaccination in COPD Patients

Study Overview
=================
Brief Summary
-----------------
Better understanding of the specificities of the vaccine response in patients with COPD

Detailed Description
-----------------
Chronic obstructive pulmonary disease (COPD) will become the third leading cause of death worldwide in 2020 (3.5 million patients, 16500 deaths in France). Its socio-economic cost is related to the handicap induced by the decline of the respiratory function, as well as to the occurrence of exacerbations, main causes of hospitalization and mortality. Since exacerbations are mostly infectious, a preventive strategy involves routine influenza vaccination. Although it is highly recommended in this population, there is no formal evidence of its effectiveness during COPD. While correlates of influenza vaccine efficacy exist, cellular and humoral responses to this vaccine have been poorly evaluated in these patients. This alteration of the vaccine response could also be integrated into an overall deficit of the response to a vaccine in these patients. As influenza virus infection is one of the most important causes of death in patients with COPD, and vaccination is the best way to prevent it, it is essential to better understand the immune response in the context of vaccination in this population. The investigator's hypothesis is that there would be a global alteration of the immunological immune response in the COPD patient involving abnormalities of lymphocyte B differentiation and the effector capacity of T lymphocytes, notably through the activation of the PD1 / PDL1 axis.

Official Title
-----------------
Immune Damage and Vaccination in COPD Patients

Conditions
-----------------
Chronic Obstructive Pulmonary Disease

Intervention / Treatment
-----------------
* Other: Anti-influenza and DTp pertussis vaccinations


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Acceptance to participate in the protocol Affiliated to a social security scheme Age between 40 and 65 years COPD patients Diagnosis of moderate to very severe COPD with FEV1 / FVC <0.7 and FEV1 <80% of predicted value, cumulative smoking greater than 10PA Indication reminder dTP pertussis when the last booster <5 years Patients without COPD FEV / FVC> 0.8 Indication reminder dTP pertussis when the last booster <5 years Indication and patient's wish for an influenza vaccination Exclusion Criteria: Refusal to participate in the study Progressive cancer and / or treated in the last 5 years, uncontrolled heart failure, connective tissue disease, inflammatory disease of the digestive tract during treatment. Exacerbation or any upper or lower respiratory infection in the previous month. Any cause of immunodepression, including long-term oral corticosteroids. Pregnant or lactating woman

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patient<br>patient with COPD | Other: Anti-influenza and DTp pertussis vaccinations<br>* Anti-influenza and DTp pertussis vaccinations will be performed during the visit by the clinical research nurse. The vaccine has been prescribed as part of the care either by the patient's physician (pulmonologist or general practitioner).<br>|
| control group<br>patient without COPD | Other: Anti-influenza and DTp pertussis vaccinations<br>* Anti-influenza and DTp pertussis vaccinations will be performed during the visit by the clinical research nurse. The vaccine has been prescribed as part of the care either by the patient's physician (pulmonologist or general practitioner).<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate and evolution of specific antibodies and Cellular B vaccine response | Rate and evolution of J30-specific antibodies according to WHO criteria Tetanus: before vaccination a rate> 0.1 IU / ml is considered protective, that is usually at a rate> 1 IU / ml after booster vaccination Influenza: antibody concentrations exceeding 0.15 μg / ml are considered protective Pertussis: anti-pertussis toxin IgG (PT) Cellular B vaccine response (plasmablast on D7) | 30 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Type of Cellular T cell response | Cellular T cell response (Tfh, Treg, TCD4 / TCD8 specific) | 15 days | 
| Transcriptomic analysis | Transcriptomic analysis in the pre- and post-vaccination period (vaccine signature) and comparison with matched subjects | 30 days | 
| Number of Lymphocyte populations | Analysis of lymphocyte populations B and T | 7 days | 
| Number of exacerbations | Number of minimal, moderate and severe exacerbations within 6 months of vaccination | 6 months |